Home › Research › TREM2 and immune genetics
Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy
Banerjee G, Ambler G, Keshavan A, Paterson RW, Foiani MS, Toombs J, Heslegrave A, Dickson JC et al.. Journal of Alzheimer's disease : JAD, 2020-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background There is limited data on cerebrospinal fluid (CSF) biomarkers in sporadic amyloid-β (Aβ) cerebral amyloid angiopathy (CAA). Objective To determine the profile of biomarkers relevant to neurodegenerative disease in the CSF of patients with CAA. Methods We performed a detailed comparison of CSF markers, comparing patients with CAA, Alzheimer's disease (AD), and control (CS) participants, recruited from the Biomarkers and Outcomes in CAA (BOCAA) study, and a Specialist Cognitive Disorders Service.
What this study adds
Evidence grade: Low
This study compared cerebrospinal fluid markers in 10 patients with cerebral amyloid angiopathy, 20 with Alzheimer's disease, and 10 controls. It is a small study describing biomarker profiles and does not show a treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Banerjee, G., Ambler, G., Keshavan, A., Paterson, R. W., Foiani, M. S., Toombs, J., et al. (2020). Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-191254
Vancouver
Banerjee G, Ambler G, Keshavan A, Paterson RW, Foiani MS, Toombs J, et al. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. Journal of Alzheimer's disease : JAD. 2020. doi:10.3233/jad-191254. PMID: 32176643.
BibTeX
@article{banerjee2020-32176643,
author = {Banerjee, G. and Ambler, G. and Keshavan, A. and Paterson, R. W. and Foiani, M. S. and Toombs, J. and Heslegrave, A. and Dickson, J. C. and others},
title = {{Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2020},
doi = {10.3233/jad-191254},
pmid = {32176643},
url = {https://doi.org/10.3233/jad-191254}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Objective To determine the profile of biomarkers relevant to neurodegenerative disease in the CSF of patients with CAA.
- Methods We performed a detailed comparison of CSF markers, comparing patients with CAA, Alzheimer's disease (AD), and control (CS) participants, recruited from the Biomarkers and Outcomes in CAA (BOCAA) study, and a Specialist Cognitive Disorders Service.
- Results We included 10 CAA, 20 AD, and 10 CS participants (mean age 68.6, 62.5, and 62.2 years, respectively).
- In unadjusted analyses, CAA patients had a distinctive CSF biomarker profile, with significantly lower (p < 0.01) median concentrations of Aβ38, Aβ40, Aβ42, sAβPPα, and sAβPPβ.
Why it matters
This study compared cerebrospinal fluid markers in 10 patients with cerebral amyloid angiopathy, 20 with Alzheimer's disease, and 10 controls. It is a small study describing biomarker profiles and does not show a treatment or cure.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 71 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.9 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 3 / 6 | Cited 3.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 2 / 4 | Cited 30 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author David John Werring: h-index 102 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32176643) |
| Free to read | 2 / 2 | Free to read |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3233/jad-191254
- PubMed: 32176643
- Original source →
- Free full text: Journal of Alzheimer s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.